Carasent Toekomstige groei

Future criteriumcontroles 4/6

Carasent zal naar verwachting groeien in winst en omzet met respectievelijk 81.4% en 18.6% per jaar. De winst per aandeel zal naar verwachting groeien met 81.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 4.2% zijn.

Belangrijke informatie

81.4%

Groei van de winst

81.4%

Groei van de winst per aandeel

Healthcare Services winstgroei	29.7%
Inkomstengroei	18.6%
Toekomstig rendement op eigen vermogen	4.2%
Dekking van analisten	Low
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0H9M - Toekomstschattingen van analisten en financiële gegevens uit het verleden (NOK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	417	44	55	107	4
12/31/2025	365	20	38	87	4
12/31/2024	280	-17	-43	38	4
9/30/2024	265	-8	-25	25	N/A
6/30/2024	254	-10	-33	19	N/A
3/31/2024	251	-56	-61	-4	N/A
12/31/2023	244	-46	-74	-4	N/A
9/30/2023	235	-64	-86	-3	N/A
6/30/2023	227	-49	-83	10	N/A
3/31/2023	210	5	-71	27	N/A
12/31/2022	195	31	-58	34	N/A
9/30/2022	179	47	-40	37	N/A
6/30/2022	168	15	-29	36	N/A
3/31/2022	154	33	-3	47	N/A
12/31/2021	137	0	-6	32	N/A
9/30/2021	117	-33	-1	29	N/A
6/30/2021	98	-21	11	33	N/A
3/31/2021	83	-46	2	21	N/A
12/31/2020	71	-38	3	19	N/A
9/30/2020	64	-14	5	21	N/A
6/30/2020	58	-4	3	18	N/A
3/31/2020	52	3	1	15	N/A
12/31/2019	48	3	2	12	N/A
9/30/2019	44	2	2	11	N/A
6/30/2019	40	0	1	7	N/A
3/31/2019	35	-3	-3	2	N/A
12/31/2018	24	-7	-2	0	N/A
9/30/2018	14	12	30	31	N/A
6/30/2018	6	18	N/A	52	N/A
3/31/2018	N/A	19	N/A	52	N/A
12/31/2017	N/A	20	N/A	51	N/A
9/30/2017	25	128	N/A	-6	N/A
6/30/2017	79	131	N/A	-16	N/A
3/31/2017	136	139	N/A	-24	N/A
12/31/2016	194	142	N/A	-36	N/A
9/30/2016	205	3	N/A	-33	N/A
6/30/2016	234	56	N/A	-60	N/A
3/31/2016	259	56	N/A	-42	N/A
12/31/2015	305	61	N/A	-32	N/A
9/30/2015	322	-31	N/A	4	N/A
6/30/2015	307	-80	N/A	24	N/A
3/31/2015	314	-84	N/A	22	N/A
12/31/2014	294	-79	N/A	24	N/A
9/30/2014	255	2	N/A	25	N/A
6/30/2014	248	2	N/A	23	N/A
3/31/2014	246	3	N/A	23	N/A
12/31/2013	254	5	N/A	29	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat 0H9M de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.1% ).

Winst versus markt: Er wordt verwacht dat 0H9M de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat 0H9M binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van 0H9M ( 18.6% per jaar) zal naar verwachting sneller groeien dan de markt UK ( 3.5% per jaar).

Hoge groei-inkomsten: De omzet van 0H9M ( 18.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 0H9M zal naar verwachting over 3 jaar laag zijn ( 4.2 %).

Carasent Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Recent updates

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Carasent Asa Approves Dividend

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Chief Executive Officer recently bought kr96k worth of stock

High number of new and inexperienced directors

Chief Executive Officer recently bought kr97k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven